

**Docket:** For access to the docket to read background documents or comments received, go to <https://www.regulations.gov> and search for “EEOC–2023–0005” or “RIN 3046–ZA02.” The received comments also will be available for review at the Commission’s library, 131 M Street NE, Suite 4NW08R, Washington, DC 20507, between the hours of 9:30 a.m. and 5:00 p.m., from November 1, 2023 until the Commission publishes the guidance in final form. You must make an appointment with library staff to review the comments in the Commission’s library.

**FOR FURTHER INFORMATION CONTACT:** Lynn Davenport, Assistant Legal Counsel, [lynn.davenport@eoc.gov](mailto:lynn.davenport@eoc.gov); Office of Legal Counsel, 202–856–7072 (voice), 1–800–669–6820 (TTY).

**SUPPLEMENTARY INFORMATION:**

**Background**

The EEOC is seeking public comments on all aspects of its proposed “Enforcement Guidance on Harassment in the Workplace” (proposed guidance) pursuant to 29 CFR part 1695. The proposed guidance presents a legal analysis of standards for harassment and employer liability applicable to claims of harassment under the equal employment opportunity statutes enforced by the Commission. The Commission posted and requested public input on a proposed guidance on workplace harassment in January 2017, which was not finalized.

The contents of the final guidance document will not have the force and effect of law and are not meant to bind the public in any way. The document is intended only to provide clarity to the public regarding Commission policies and existing requirements under the law. The standards discussed under EEOC-enforced laws will not necessarily apply to allegations of unlawful harassment under other Federal laws or under State or local laws.

For the Commission:  
**Charlotte A. Burrows,**  
*Chair.*  
[FR Doc. 2023–21644 Filed 9–29–23; 8:45 am]  
**BILLING CODE 6570–01–P**

**FARM CREDIT SYSTEM INSURANCE CORPORATION**

**Board of Directors Meeting**

**SUMMARY:** Notice of the forthcoming regular meeting of the Board of Directors of the Farm Credit System Insurance Corporation (FCSIC), is hereby given in

accordance with the provisions of the Bylaws of the FCSIC.

**DATES:** 10 a.m., Wednesday, October 11, 2023.

**ADDRESSES:** You may observe the open portions of this meeting in person at 1501 Farm Credit Drive, McLean, Virginia 22102–5090, or virtually. If you would like to virtually attend, at least 24 hours in advance, visit [FCSIC.gov](https://www.fcsic.gov), select “News & Events,” then select “Board Meetings.” From there, access the linked “Instructions for board meeting visitors” and complete the described registration process.

**FOR FURTHER INFORMATION CONTACT:** If you need more information or assistance for accessibility reasons, or have questions, contact Ashley Waldron, Secretary to the Board. Telephone: 703–883–4009. TTY: 703–883–4056.

**SUPPLEMENTARY INFORMATION:** Parts of this meeting will be open to the public. The rest of the meeting will be closed to the public. The following matters will be considered:

**Portions Open to the Public**

- Approval of Minutes for July 12, 2023
- Quarterly FCSIC Financial Reports
- Quarterly Report on Insured Obligations
- Quarterly Report on Annual Performance Plan
- Annual Performance Plan
- Budget 2024–2025

**Portions Closed to the Public**

- Confidential Report on Insurance Risk

**Ashley Waldron,**  
*Secretary to the Board.*  
[FR Doc. 2023–21681 Filed 9–29–23; 8:45 am]  
**BILLING CODE 6705–01–P**

**FEDERAL RESERVE SYSTEM**

**Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible Nonbanking Activities**

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR part 225) to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington DC 20551–0001, not later than October 17, 2023.

*A. Federal Reserve Bank of New York* (Ivan J. Hurlwitz, Head of Bank Applications) 33 Liberty Street, New York, New York 10045–0001. Comments can also be sent electronically to [comments.applications@ny.frb.org](mailto:comments.applications@ny.frb.org):

1. *The Goldman Sachs Group, Inc., New York, New York*; to engage in community development activities pursuant to section 225.28(b)(12) of the Board’s Regulation Y.

Board of Governors of the Federal Reserve System.

**Michele Taylor Fennell,**  
*Deputy Associate Secretary of the Board.*  
[FR Doc. 2023–21737 Filed 9–29–23; 8:45 am]  
**BILLING CODE P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Solicitation of Nominations for Appointment to the Advisory Committee on Breast Cancer in Young Women (ACBCYW)**

**ACTION:** Notice.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC) is seeking nominations for membership on the ACBCYW. The ACBCYW consists of 15 experts in fields associated with breast cancer, disease prevention, early detection, diagnosis, public health, social marketing, genetic screening and counseling, treatment, rehabilitation, palliative care, and survivorship in

young women, or in related disciplines with a specific focus on young women.

**DATES:** Nominations for membership on the ACBCYW must be received no later than November 10, 2023. Packages received after this time will not be considered for the current membership cycle.

**ADDRESSES:** All nominations should be mailed to Kimberly E. Smith, MBA, MHA, c/o ACBCYW Secretariat, Centers for Disease Control and Prevention, 3719 North Peachtree Road, Building 100, Chamblee, Georgia 30341 or emailed (recommended) to [acbcyw@cdc.gov](mailto:acbcyw@cdc.gov).

**FOR FURTHER INFORMATION CONTACT:** Kimberly E. Smith, MBA, MHA, Designated Federal Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway NE, Mailstop S107-4, Atlanta, Georgia 30341, Telephone: (404) 498-0073; [acbcyw@cdc.gov](mailto:acbcyw@cdc.gov).

**SUPPLEMENTARY INFORMATION:**

Nominations are being sought for individuals who have expertise and qualifications necessary to contribute to the accomplishments of the committee's objectives. Nominees will be selected based on expertise in the fields of breast health, breast cancer, disease prevention and risk reduction, survivorship (including metastatic breast cancer), hereditary breast and ovarian cancer (HBOC), or in related disciplines with a specific focus on young women. Persons with personal experience with early onset breast cancer are also eligible to apply. This includes but may not be limited to breast cancer survivors <45 years of age and caregivers of said persons. Federal employees will not be considered for membership. Members may be invited to serve up to four-year terms. Selection of members is based on candidates' qualifications to contribute to the accomplishment of ACBCYW objectives (<http://www.cdc.gov/maso/facm/facmacbcyw.html>).

The U.S. Department of Health and Human Services policy stipulates that committee membership be balanced in terms of points of view represented, and the committee's function. Appointments shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, gender identity, HIV status, disability, and cultural, religious, or socioeconomic status. Nominees must be U.S. citizens and cannot be full-time employees of the U.S. Government. Current participation on federal workgroups or prior experience serving on a federal advisory committee does not disqualify a candidate; however, HHS policy is to avoid excessive individual service on

advisory committees and multiple committee memberships. Committee members are Special Government Employees, requiring the filing of financial disclosure reports at the beginning and annually during their terms. CDC reviews potential candidates for ACBCYW membership each year and provides a slate of nominees for consideration to the Secretary of HHS for final selection. HHS notifies selected candidates of their appointment near the start of the term in November 2024, or as soon as the HHS selection process is completed. Note that the need for different expertise varies from year to year and a candidate who is not selected in one year may be reconsidered in a subsequent year. SGE nominees must be U.S. citizens and cannot be full-time employees of the U.S. Government. Candidates should submit the following items:

- Current curriculum vitae, including complete contact information (telephone numbers, mailing address, email address).
- At least one letter of recommendation from person(s) not employed by the U.S. Department of Health and Human Services. (Candidates may submit letter(s) from current HHS employees if they wish, but at least one letter must be submitted by a person not employed by an HHS agency (e.g., CDC, NIH, FDA, etc.).
- A short biography (150 words or less).

Nominations may be submitted by the candidate him- or herself, or by the person/organization recommending the candidate.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023-21568 Filed 9-29-23; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

[Docket No. CDC-2023-0076]

**Advisory Committee on Immunization Practices (ACIP); Amended Notice of Meeting**

**AGENCY:** Centers for Disease Control and Prevention, Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public.

**FOR FURTHER INFORMATION CONTACT:** Stephanie Thomas, Committee Management Specialist, Advisory Committee on Immunization Practices, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta, Georgia 30329-4027. Telephone: (404) 639-8836; Email: [ACIP@cdc.gov](mailto:ACIP@cdc.gov).

**SUPPLEMENTARY INFORMATION:** Notice is hereby given of a change in the meeting of the Advisory Committee on Immunization Practices (ACIP); September 22, 2023, 10 a.m. to 5 p.m., EDT (times subject to change, see the ACIP website for updates: <https://www.cdc.gov/vaccines/acip/index.html>), in the original **Federal Register** notice.

Notice of the virtual meeting was published in the **Federal Register** on September 6, 2023, Volume 88, Number 171, pages 60945-60946.

Notice of the virtual meeting is being amended to add an additional agenda item in the matters to be considered, which should read as follows:

*Matters to be Considered:* The agenda will include discussions of maternal respiratory syncytial virus (RSV) vaccine, child/adolescent immunization schedules and adult immunization schedule. A recommendation vote for maternal RSV vaccine is scheduled. A Vaccines for Children vote is scheduled for maternal RSV vaccine. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit <https://www.cdc.gov/vaccines/acip/meetings/index.html>.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease